Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (211${count})

  • Rapid Response Innovation Awards, 2014
    Effect of Dietary Ketosis On Alpha-Synuclein Accumulation

    Study Rationale:
    A key feature of Parkinson’s disease is abnormal accumulation of the protein alpha-synuclein. Production of organic compounds called ketones is a normal metabolic process that occurs...

  • Access to Data and Biospecimens, 2015
    BioFIND: Analysis of A-beta, Tau and P-tau in CSF Samples

    Study Rationale: Mixed pathology is common in all neurodegenerative diseases including Parkinson’s disease (PD).  Three cerebrospinal fluid (CSF) biomarkers, Ab1-42, t-tau and p-tau181, provide an...

  • PD Subtypes, 2007
    Defining PD Subtypes Based on Patterns of Long-term Outcome

    The purpose of our study is to identify Parkinson’s disease subtypes based on how individuals are doing approximately seven to eight years after diagnosis. Some patients have few symptoms at this time...

  • Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025
    GBA1 Consortium: Joint Analysis to Inform Clinical Trials

    Study Rationale: Variants in the GB1A gene represent the most important genetic risk factor for Parkinson’s disease (PD) across the globe. However, different GBA1 variants are associated with varied...

  • PPMI Data Challenge, 2016
    Subtyping Parkinson’s Disease with Deep Learning Models (2016 PPMI Data Challenge Winner)

    Study Rationale:
    As Parkinson's disease (PD) is highly heterogeneous, identifying coherent PD subtypes is crucial for understanding the underlying mechanism of the disease and designing and testing...

  • Target Advancement Program, 2016
    Alpha-synuclein Toxicity in LRRK2 Pre-clinical Models and Rescue by LRRK2 Silencing

    Study Rationale:
    Genetic mutations that alter the function of the LRRK2 protein increase the risk of developing a form of Parkinson's disease (PD). Age and other environmental factors combine with...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.